Eli Lilly Raises Alarm Over Tirzepatide Compounding Risks

Eli Lilly and Company issues a public warning regarding potential safety risks associated with the compounding of tirzepatide with vitamin B12 and other additives. Tests reveal significant impurities, prompting the company to notify the FDA and urge action against unlawful mass compounding practices that threaten patient safety.

Eli Lilly and Company has publicly warned about the serious safety risks linked to the compounding of tirzepatide with vitamin B12. Tests conducted by the company found significant impurity levels resulting from a chemical reaction between the two substances.

This discovery has led Eli Lilly to alert the U.S. Food and Drug Administration (FDA), urging the regulatory body to take stringent measures against unauthorized mass compounding that endangers public health.

Additionally, the company has identified other critical safety concerns in compounded tirzepatide products, citing issues like bacterial contamination and elevated endotoxin levels. Eli Lilly calls for a recall of all such untested compounds to safeguard patient safety.